Visible-light-driven photocatalysts attract great interest because they can utilize more sunlight for reactions than conventional photocatalysts. A novel visible-light-driven photocatalyst AgI/Bismuth oxychloride (Bi 12 O 17 Cl 2 ) hybrid was synthesized by a hydrothermal-precipitation method. Several characterization tools, such as X-ray powder diffraction (XRD), scanning electron microscopy (SEM), high-resolution transmission electron microscopy (HRTEM), X-ray photoelectron spectroscopy (XPS), and UV–vis diffuse reflectance spectroscopy (DRS) were employed to study the phase structures, morphologies, and optical properties of the fabricated photocatalysts. These characterizations indicated that AgI nanoparticles were evenly distributed on the surface of Bi 12 O 17 Cl 2, and heterostructures were formed. The photochemical characterizations demonstrated that the promoted separation of carrier transfer in the AgI/Bi 12 O 17 C l2 heterojunction was achieved. The degradation rate of sulfamethazine (SMZ) by AgI/Bi 12 O 17 Cl 2 was about 7.8 times and 35.2 times higher than that of pristine Bi 12 O 17 Cl 2 and BiOCl under visible-light-driven photocatalysts, respectively. It was also found that the amount of AgI in the AgI/Bi 12 O 17 Cl 2 composites played an important role in photocatalytic activity, and the optimized ratio was 25%. The AgI/Bi 12 O 17 Cl 2 shows good catalytic stability and maintains similar reactivity after four cycles. Furthermore, the degradation intermediates of SMZ were identified by HPLC-MS, and the photocatalytic mechanism was proposed. These findings highlight the role of Bi 12 O 17 Cl 2 on contaminant elimination and open avenues for the rational design of highly efficient photocatalysts.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: